



IMAGE COPYRIGHT: REUTERS / Ali Jarekji

# THE CMR INTERNATIONAL 2012 ASIA PACIFIC FACTBOOK



THE *CMR INTERNATIONAL* 2012 ASIA PACIFIC PHARMACEUTICAL R&D FACTBOOK IS NOW AVAILABLE.

TO ORDER YOUR COPY PLEASE CONTACT US AT [cmr@thomsonreuters.com](mailto:cmr@thomsonreuters.com) OR VISIT [cmr.thomsonreuters.com/shop](http://cmr.thomsonreuters.com/shop)

The *CMR International* 2012 Asia Pacific Pharmaceutical R&D Factbook is the definitive up-to-date business-planning report for decision-makers in R&D, corporate finance, business strategy, marketing planning and corporate communications for any professional concerned with the Asia Pacific Region.

This essential report will can help you to:

- Gain an in-depth understanding of industry dynamics and trends within the region
- Understand the changing roles of Asian countries in innovative R&D
- Make informed decisions regarding clinical trial placement
- Understand the strengths of certain countries with respect to clinical trial execution
- Assess where regulatory challenges may exist
- Set internal performance targets that will motivate and challenge your business

Each finding is presented in a clear, easily-understood chart, accompanied by a succinct commentary highlighting the key message, and an explanation of the methodology used and the definitions applied.

The following pages outline the complete **LIST OF FIGURES**.

[cmr.thomsonreuters.com](http://cmr.thomsonreuters.com)



THOMSON REUTERS™

# LIST OF FIGURES

## CHAPTER 1. OVERVIEW

- 1.1 Global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output between 2001 and 2011
- 1.2 Global pharmaceutical R&D expenditure between 2001 and 2015p
- 1.3 Regional distribution of total R&D expenditure in 2010 and 2011
- 1.4 Regional distribution of total R&D expenditure in 2011
- 1.5 Global pharmaceutical sales between 2001 and 2015p
- 1.6 Market potential in Asia Pacific
- 1.7 Number of New Molecular Entities and New Active Substances first launched onto the world market between 2002 and 2011
- 1.8 Region of first launch for New Molecular Entities between 2002 and 2011
- 1.9 Number of New Molecular Entities first launched into Asia Pacific countries between 2001 and 2011
- 1.10 Major merger and acquisition activity in Japan, 2002-2012
- 1.11 Major non-domestic acquisitions by Japanese companies, 2002-2012

## CHAPTER 2. R&D PIPELINE VOLUME

- 2.1 Trend in mean number of active substances developed for first launch globally and in Japan between 2007 and 2010
- 2.2 Indexed trend in number of active substances entering each phase of development globally and in Japan between 2007 and 2010
- 2.3 Number of projects terminated in Phase III between 2006 and 2011
- 2.4 Between phase success rates: Japan and Global, 2008 - 2010
- 2.5 Global and Japanese probability of success to market between 2008 and 2010
- 2.6 Changes in the number of projects in each development phase between 2006 and 2010 by active substance origin in Japan
- 2.7 Number of studies achieving key milestones between 2007 and 2010 globally
- 2.8 Number of studies achieving key milestones between 2007 and 2010 in Japan

## CHAPTER 3. REGIONAL COMPARISONS

- 3.1 Interval durations for intervals completed between 2006 and 2010, Japan versus Global
- 3.2 Proportional change of enrolled patients in each geographical region between 2004 and 2010
- 3.3 Median interval duration between 'Submission to local authority' and 'All local approvals secured' by country: 2006-2010
- 3.4 Key barriers or competitive factors for undertaking clinical development as part of global drug development in each country
- 3.5 Regulatory requirements deemed to be above the ICH 'norm' to initiate a trial
- 3.6 Ethical approval issues by country
- 3.7 Regulatory approval issues by country
- 3.8 Main barriers to bringing global clinical trial programmes to Asia and Latin America
- 3.9 Composite clinical study interval durations by country in 2010, excluding treatment duration
- 3.10 Median interval duration between 'First patient enrolled' and 'Last patient enrolled' by country: 2006-2010
- 3.11 Median number of sites per study by country between 2006 and 2010
- 3.12 Proportion of low performing sites by country between 2006 and 2010
- 3.13 Median Interval duration between 'Site ethics/IRB approval' and 'Site initiated' by country: 2006-2010
- 3.14 Median interval duration between 'Site initiated' and 'First patient enrolled' by country: 2006-2010
- 3.15 Number of FDA forms by country between 2005 and 2009
- 3.16 Median time in roll out to emerging market countries for new active substances approved between 2006 and 2009
- 3.17 Median regulatory approval times from date of submission to approval for new active substances approved between 2006 and 2009
- 3.18 Median time between first world approval and submission in emerging market countries for new active substances approved between 2005 and 2009
- 3.19 Median lag time from Global to Japanese activities between 2006 and 2010
- 3.20 Median lag time from Global to Japanese activities between 2006 and 2010, by year
- 3.21 Score card: Country performance comparison

## CHAPTER 4. PATENTS AND GLOBAL GENERICS MARKETS

- 4.1 Top 10 drugs by global sales in 2011
- 4.2 Sales forecast for global top 10 drugs in 2018
- 4.3 Number of pharmaceutical patent applications and granted patents for 5 major patent issuing authorities between 2001 and 2011
- 4.4 Generic drug companies deals by pharmaceutical companies
- 4.5 Experience of generic API manufacturers with regard to supplying the regulated markets
- 4.6 Current experience of generic API manufacturers with regard to supplying the regulated markets
- 4.7 Number of European certificates of suitability (COS) granted between 2002 and 2011 by location of company headquarters
- 4.8 Number of US DMF granted each year between 2002 and 2011 by location of company headquarters
- 4.9 API plants inspected by FDA in each year between 2003-2011 by location of company headquarters
- 4.10 Significant merger & acquisitions in the regulated markets by Indian and Chinese companies between 2004 and 2011
- 4.11 Number of ANDA final approvals in each year between 2009 and 2011 by country of origin
- 4.12 Number of ANDA approvals for Indian generic companies between 2002 and 2011
- 4.13 Non-M&A deals making between Indian generics between 2003 and 2011
- 4.14 Total number of paragraph IV patent challenges by Indian companies
- 4.15 Interval durations from the first US DMF date to the first ANDA approval date by Indian and Chinese generic companies
- 4.16 Number and value of deals made by Indian generic companies to investigate innovative treatments
- 4.17 Number of new molecules in development by companies with a primary focus in generic products between 2007 and 2011
- 4.18 Biotech capabilities among the top Indian companies
- 4.19 Biotech capabilities among the top Chinese companies
- 4.20 Biologic development in Japan and South Korea

### CMR CONTACTS

#### Phil Miller

Director, Product Strategy  
+ 44 (0) 207 433 4163  
+ 44 (0) 782 789 5170

#### Ben Mussell

Practice Consultant,  
Clinical Professional Services  
+44 (0) 207 433 4289

The Johnson Building  
77 Hatton Garden  
London  
EC1N 8JS

**T** +44 (0) 20 7433 4000  
**F** +44 (0) 20 7433 4310

[info@cmr.thomsonreuters.com](mailto:info@cmr.thomsonreuters.com)

### THOMSON REUTERS REGIONAL OFFICES

#### North America

Philadelphia +1 800 336 4474  
+1 215 386 0100

#### Latin America

+55 11 8370 9845

#### Europe, Middle East, and Africa

London +44 20 7433 4000

#### Asia Pacific

Singapore +65 6775 5088  
Tokyo +81 3 5218 6500

For a complete office list visit:

[ip-science.thomsonreuters.com/  
contact](http://ip-science.thomsonreuters.com/contact)

